Danaher announced a cash acquisition of Masimo valued at roughly $9.9–$10 billion to expand its acute-care diagnostics and patient-monitoring portfolio. The deal consolidates pulse oximetry and bedside monitoring technology into Danaher’s diagnostics footprint and follows contemporaneous industry moves to integrate monitoring and diagnostic data across care settings. The transaction comes as Danaher and other large med‑tech players push for scale in hospital workflows and continuous patient monitoring. Market commentary noted strategic rationales including cross-selling, data integration opportunities, and supply-chain synergies. Short-form industry briefs also flagged related diagnostic collaborations and CDC initiatives that may amplify demand for rapid and deployable testing solutions.